Kevin Tang, an activist biotech investor, has consolidated control of Aurinia Pharmaceuticals and replaced the CEO and senior management, according to a securities filing. The filing shows Tang moved quickly to install new leadership after winning pivotal board influence. The shake-up centralizes governance around an investor known for takeover plays; investors and partners will watch for strategic shifts in Aurinia’s pipeline prioritization and capital allocation. The filing did not detail immediate clinical- or product-level changes.